Open Access Research article

Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program

Ebru Tekinturhan1, Etienne Audureau2, Marie-Pierre Tavolacci3, Patricia Garcia-Gonzalez4, Joël Ladner3 and Joseph Saba1*

Author Affiliations

1 Axios International, 7, Boulevard de la Madeleine, Paris 75001, France

2 Biostatistics and Epidemiology Unit, Hôtel Dieu, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Sorbonne Paris Cité, Paris, France

3 Department of Epidemiology and Public Health, Rouen University Hospital, Rouen, France

4 The Max Foundation, Edmonds, WA, USA

For all author emails, please log on.

BMC Health Services Research 2013, 13:304  doi:10.1186/1472-6963-13-304

Published: 10 August 2013



Limited access to drugs is a crucial barrier to reducing the growing impact of cancer in low- and middle-income countries. Approaches based on drug donations or adaptive pricing strategies yield promising but varying results across countries or programs, The Glivec International Patient Assistance Program (GIPAP) is a program designed to provide imatinib free of charge to patients with chronic myeloid leukemia (CML) or gastrointestinal stromal tumors (GIST). The objective of this work was to identify institutional factors associated with enrollment and patient survival in GIPAP.


We analyzed follow-up data from 4,946 patients participating in 47 institutions within 44 countries between 2003 and 2010. Active status in the program was considered as a proxy for survival.


Presence of ≥1 hematologist or oncologist at the institution was associated with increased patient enrollment. After adjusting for individual factors such as age (>55 years: Hazard Ratio [HR] = 1.42 [1.16; 1.73]; p = 0.001) and initial stage of disease (accelerated or blast crisis at diagnosis: HR = 4.16 [1.87; 9.25]; p < 10-4), increased survival was found in institutions with research capabilities (HR = 0.55 [0.35; 0.86]; p = 0.01) and those with enrollment of >5 patients/year into GIPAP (HR = 0.48 [0.35; 0.67]; p < 10-4), while a non-significant trend for decreased survival was found for treatment at a public institution (HR = 1.32 [0.95; 1.84]; p = 0.10). The negative impact of an accelerated form of CML was attenuated by the presence of ≥1 hematologist or oncologist at the institution (interaction term HR = 0.43 [0.18; 0.99]; p = 0.05).


Application of these findings to the support and selection of institutions participating in GIPAP may help to optimize care and outcomes for CML and GIST patients in the developing world. These results may also be applicable to the treatment of patients with other forms of cancer, due to the overlap of infrastructure and staff resources used to treat a variety of cancer indications. A multi-sector approach is required to address these barriers.

Cancer; Access to medication; Enrollment; Implementation; Survival